alcohol use disorder

Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has taken a big step toward Phase III clinical trial initiation today. The company has submitted a Clinical Trial Application...

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first patient in Phase 2 trial of OPNT002, nasal naltrexone, for Alcohol Use Disorder (AUD).  The trial will determine whether OPNT002 reduces heavy drinking as measured by a change in the World Health Organization (WHO)...

Adial Pharmaceuticals Inc (NASDAQ: ADIL) has received notice from the FDA that its request for Fast Track Designation for AD04 in Alcohol Use Disorder has been denied at this time.  The FDA stated that the Company has not yet demonstrated that the product shows potential, and the...

MediciNov Inc (NASDAQ: MNOV) has announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Nature's Translational Psychiatry. The trial was funded by the Center for Study of Opioid Receptors and Drugs of Abuse. The...

Shares of nano-cap biotech Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) were volatile Thursday morning following an announcement concerning its pre-investigational new drug application meeting with the U.S Food and Drug Administration. Following the receipt of the minutes of the Type B, pre-...